Adult T-cell leukemia/lymphoma and HTLV-1

被引：34

作者：

Mahieux R. ^{[1
]}

Gessain A. ^{[1
]}

机构：

[1] CNRS URA 3015, Department of Virology, Institut Pasteur, 75724 Paris Cedex 15

来源：

Current Hematologic Malignancy Reports | 2007年 / 2卷 / 4期

关键词：

Alemtuzumab; Arsenic Trioxide; Proviral Load; ATLL Cell; ATLL Patient;

D O I：

10.1007/s11899-007-0035-x

中图分类号：

学科分类号：

摘要：

Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago. HTLV-1 infects 15 to 20 million individuals worldwide. This oncoretrovirus can be transmitted in three ways: horizontally (sexually), vertically (mother to child), and via blood transfusion. HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1- associated myelopathy (TSP/HAM). ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type. Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations. This article discusses a number of recent treatments including antiretroviral therapy, aggressive chemotherapy, and allogeneic bone-marrow transplantation, as well as new drugs. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：257 / 264

页数：7

共 55 条

[41]

Mori N., Yamada Y., Ikeda S., Et al., Bay 11-7082 inhibits transcription factor NF-κB and induces apoptosis of HTLV-I-infected T-cell lines and primary adult T-cell leukemia cells, Blood, 100, pp. 1828-1834, (2002)

[42]

Nasr R., El-Sabban M.E., Karam J.A., Et al., Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma, Oncogene, 24, pp. 419-430, (2005)

[43]

Watanabe M., Ohsugi T., Shoda M., Et al., Dual targeting of transformed and untransformed HTLV-1-infected T cells by DHMEQ, a potent and selective inhibitor of NF-κB, as a strategy for chemoprevention and therapy of adult T-cell leukemia, Blood, 106, pp. 2462-2471, (2005)

[44]

Ishitsuka K., Hanada S., Suzuki S., Et al., Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids, Br J Haematol, 103, pp. 721-728, (1998)

[45]

Bazarbachi A., El-Sabban M.E., Nasr R., Et al., Arsenic trioxide and interferon-α synergize to induce cell cycle arrest and apoptosis in human T-cell lymphotropic virus type I- transformed cells, Blood, 93, pp. 278-283, (1999)

[46]

El-Sabban M.E., Nasr R., Dbaibo G., Et al., Arsenic-interferon-α- triggered apoptosis in HTLV-I transformed cells is associated with Tax down-regulation and reversal of NF-κB activation, Blood, 96, pp. 2849-2855, (2000)

[47]

Mahieux R., Pise-Masison C., Gessain A., Et al., Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage, Blood, 98, pp. 3762-3769, (2001)

[48]

Hermine O., Dombret H., Poupon J., Et al., Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma, Hematol J, 5, pp. 130-134, (2004)

[49]

Waldmann T.A., Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey, J Clin Immunol, 27, pp. 1-18, (2007)

[50]

Moura I.C., Lepelletier Y., Arnulf B., Et al., A neutralizing monoclonal antibody (mAb A24) directed against the transferrin receptor induces apoptosis of tumor T lymphocytes from ATL patients, Blood, 103, pp. 1838-1845, (2004)

← 1 2 3 4 5 6 →